Clinical trial · Observational
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels
NCT06129812CI-TRIAL-00071272completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoadjuvant | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- resectable PDAC with no contact to major vessels (R-no contact)
- interventionNames
- Drug: Neoadjuvant treatment
- label
- resectable PDAC with contact PV/SMV of ≤180° (R-contact)
- interventionNames
- Drug: Neoadjuvant treatment
- label
- borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)
- interventionNames
- Drug: Neoadjuvant treatment
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC) * Between January 2007 and June 2021 at Seoul National University Hospital Exclusion Criteria: * Patients who had borderline resectable PDAC with arterial invasion * Patients who received chemotherapy as initial treatment and did not undergo surgery * Incomplete follow-up data for analysis
References
Publications (0)
Data not yet available
No reference posted for this study.